Champlain Investment Partners LLC increased its holdings in Omnicell, Inc. (NASDAQ:OMCL – Free Report) by 16.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,753,205 shares of the company’s stock after purchasing an additional 241,235 shares during the period. Champlain Investment Partners LLC owned 3.82% of Omnicell worth $51,246,000 as of its most recent SEC filing.
Several other institutional investors have also recently added to or reduced their stakes in OMCL. Connors Investor Services Inc. increased its position in Omnicell by 64.6% during the first quarter. Connors Investor Services Inc. now owns 95,547 shares of the company’s stock worth $2,793,000 after purchasing an additional 37,502 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Omnicell by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company’s stock worth $165,200,000 after buying an additional 80,312 shares during the period. State Board of Administration of Florida Retirement System boosted its holdings in Omnicell by 14.3% in the first quarter. State Board of Administration of Florida Retirement System now owns 14,660 shares of the company’s stock valued at $429,000 after acquiring an additional 1,830 shares during the last quarter. Entropy Technologies LP acquired a new stake in Omnicell during the first quarter worth about $227,000. Finally, ProShare Advisors LLC raised its holdings in shares of Omnicell by 7.4% in the 1st quarter. ProShare Advisors LLC now owns 9,076 shares of the company’s stock worth $265,000 after purchasing an additional 626 shares during the period. 97.70% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of analysts recently issued reports on the stock. Benchmark reissued a “buy” rating and set a $38.00 target price on shares of Omnicell in a research report on Monday, July 15th. StockNews.com lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Tuesday, July 16th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, Omnicell has a consensus rating of “Hold” and a consensus price target of $42.20.
Omnicell Stock Up 4.4 %
Omnicell stock traded up $1.22 during midday trading on Tuesday, hitting $29.26. 224,463 shares of the stock were exchanged, compared to its average volume of 517,561. Omnicell, Inc. has a 1 year low of $25.12 and a 1 year high of $66.65. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.38 and a quick ratio of 2.13. The firm has a market cap of $1.34 billion, a P/E ratio of -60.96, a P/E/G ratio of 97.59 and a beta of 0.80. The company has a 50 day moving average price of $28.81 and a two-hundred day moving average price of $29.23.
Omnicell (NASDAQ:OMCL – Get Free Report) last announced its earnings results on Thursday, May 2nd. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.17. The business had revenue of $246.15 million for the quarter, compared to analyst estimates of $235.70 million. Omnicell had a positive return on equity of 2.41% and a negative net margin of 1.91%. On average, sell-side analysts predict that Omnicell, Inc. will post 0.2 earnings per share for the current fiscal year.
Omnicell Company Profile
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
Featured Articles
- Five stocks we like better than Omnicell
- How to invest in marijuana stocks in 7 steps
- ScottsMiracle-Gro Stock Blooms After Investor Day Optimism
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Leading Beverage Company’s Stock Bubbles Higher: Rally Ahead
- Insider Trades May Not Tell You What You Think
- Can This Meme Stock Stage One Last Rally?
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.